{"pmid":32360497,"pmcid":"PMC7189187","title":"The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France.","text":["The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France.","A new virus, SARS-CoV-2, has spread world-wide since December 2019, probably affecting millions of people and killing thousands. Failure to anticipate the spread of the virus now seriously threatens many health systems. We have designed a model for predicting the evolution of the SARS-CoV-2 epidemic in France, which is based on seroprevalence and makes it possible to anticipate the deconfinement strategy.","J Infect","Dimeglio, Chloe","Loubes, Jean-Michel","Deporte, Benjamin","Dubois, Martine","Latour, Justine","Mansuy, Jean-Michel","Izopet, Jacques","32360497"],"abstract":["A new virus, SARS-CoV-2, has spread world-wide since December 2019, probably affecting millions of people and killing thousands. Failure to anticipate the spread of the virus now seriously threatens many health systems. We have designed a model for predicting the evolution of the SARS-CoV-2 epidemic in France, which is based on seroprevalence and makes it possible to anticipate the deconfinement strategy."],"journal":"J Infect","authors":["Dimeglio, Chloe","Loubes, Jean-Michel","Deporte, Benjamin","Dubois, Martine","Latour, Justine","Mansuy, Jean-Michel","Izopet, Jacques"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360497","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jinf.2020.04.031","keywords":["sars-cov-2","deconfinement","seroprevalence","statistical model"],"locations":["France","France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1666138495528206336,"score":9.490897,"similar":[{"pmid":32360907,"pmcid":"PMC7175852","title":"Estimation of COVID-19 prevalence in Italy, Spain, and France.","text":["Estimation of COVID-19 prevalence in Italy, Spain, and France.","At the end of December 2019, coronavirus disease 2019 (COVID-19) appeared in Wuhan city, China. As of April 15, 2020, >1.9 million COVID-19 cases were confirmed worldwide, including >120,000 deaths. There is an urgent need to monitor and predict COVID-19 prevalence to control this spread more effectively. Time series models are significant in predicting the impact of the COVID-19 outbreak and taking the necessary measures to respond to this crisis. In this study, Auto-Regressive Integrated Moving Average (ARIMA) models were developed to predict the epidemiological trend of COVID-19 prevalence of Italy, Spain, and France, the most affected countries of Europe. The prevalence data of COVID-19 from 21 February 2020 to 15 April 2020 were collected from the World Health Organization website. Several ARIMA models were formulated with different ARIMA parameters. ARIMA (0,2,1), ARIMA (1,2,0), and ARIMA (0,2,1) models with the lowest MAPE values (4.7520, 5.8486, and 5.6335) were selected as the best models for Italy, Spain, and France, respectively. This study shows that ARIMA models are suitable for predicting the prevalence of COVID-19 in the future. The results of the analysis can shed light on understanding the trends of the outbreak and give an idea of the epidemiological stage of these regions. Besides, the prediction of COVID-19 prevalence trends of Italy, Spain, and France can help take precautions and policy formulation for this epidemic in other countries.","Sci Total Environ","Ceylan, Zeynep","32360907"],"abstract":["At the end of December 2019, coronavirus disease 2019 (COVID-19) appeared in Wuhan city, China. As of April 15, 2020, >1.9 million COVID-19 cases were confirmed worldwide, including >120,000 deaths. There is an urgent need to monitor and predict COVID-19 prevalence to control this spread more effectively. Time series models are significant in predicting the impact of the COVID-19 outbreak and taking the necessary measures to respond to this crisis. In this study, Auto-Regressive Integrated Moving Average (ARIMA) models were developed to predict the epidemiological trend of COVID-19 prevalence of Italy, Spain, and France, the most affected countries of Europe. The prevalence data of COVID-19 from 21 February 2020 to 15 April 2020 were collected from the World Health Organization website. Several ARIMA models were formulated with different ARIMA parameters. ARIMA (0,2,1), ARIMA (1,2,0), and ARIMA (0,2,1) models with the lowest MAPE values (4.7520, 5.8486, and 5.6335) were selected as the best models for Italy, Spain, and France, respectively. This study shows that ARIMA models are suitable for predicting the prevalence of COVID-19 in the future. The results of the analysis can shed light on understanding the trends of the outbreak and give an idea of the epidemiological stage of these regions. Besides, the prediction of COVID-19 prevalence trends of Italy, Spain, and France can help take precautions and policy formulation for this epidemic in other countries."],"journal":"Sci Total Environ","authors":["Ceylan, Zeynep"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360907","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.scitotenv.2020.138817","keywords":["arima","covid-19","forecasting","infection disease","pandemic","time series"],"locations":["Wuhan","China","Italy","Spain","France","Italy","Spain","France","Italy","Spain","France","Italy","Spain","France"],"countries":["Italy","China","Spain","France"],"countries_codes":["ITA|Italy","CHN|China","ESP|Spain","FRA|France"],"topics":["Epidemic Forecasting","Prevention"],"weight":1,"_version_":1666138495492554753,"score":102.31597},{"pmid":32404476,"title":"Estimating the burden of SARS-CoV-2 in France.","text":["Estimating the burden of SARS-CoV-2 in France.","France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 3.6% of infected individuals are hospitalized and 0.7% die, ranging from 0.001% in those <20 years of age (ya) to 10.1% in those >80ya. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project 2.8 million (range: 1.8-4.7) people, or 4.4% (range: 2.8-7.2) of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown.","Science","Salje, Henrik","Tran Kiem, Cecile","Lefrancq, Noemie","Courtejoie, Noemie","Bosetti, Paolo","Paireau, Juliette","Andronico, Alessio","Hoze, Nathanael","Richet, Jehanne","Dubost, Claire-Lise","Le Strat, Yann","Lessler, Justin","Levy-Bruhl, Daniel","Fontanet, Arnaud","Opatowski, Lulla","Boelle, Pierre-Yves","Cauchemez, Simon","32404476"],"abstract":["France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 3.6% of infected individuals are hospitalized and 0.7% die, ranging from 0.001% in those <20 years of age (ya) to 10.1% in those >80ya. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project 2.8 million (range: 1.8-4.7) people, or 4.4% (range: 2.8-7.2) of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown."],"journal":"Science","authors":["Salje, Henrik","Tran Kiem, Cecile","Lefrancq, Noemie","Courtejoie, Noemie","Bosetti, Paolo","Paireau, Juliette","Andronico, Alessio","Hoze, Nathanael","Richet, Jehanne","Dubost, Claire-Lise","Le Strat, Yann","Lessler, Justin","Levy-Bruhl, Daniel","Fontanet, Arnaud","Opatowski, Lulla","Boelle, Pierre-Yves","Cauchemez, Simon"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404476","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1126/science.abc3517","locations":["France","France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention","Epidemic Forecasting"],"weight":1,"_version_":1666802845543825408,"score":94.280914},{"pmid":32386464,"title":"A primer on COVID-19 Mathematical Models.","text":["A primer on COVID-19 Mathematical Models.","The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) disease has led to a wide-spread global pandemic (1). COVID-19 symptoms and mortality are disproportionately more severe in people with obesity and obesity related comorbidities (2, 3). This is of concern for the United States, where ~42% have obesity and of these, 85% have type 2 diabetes.","Obesity (Silver Spring)","Thomas, Diana M","Sturdivant, Rodney","Dhurandhar, Nikhil V","Debroy, Swati","Clark, Nicholas","32386464"],"abstract":["The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) disease has led to a wide-spread global pandemic (1). COVID-19 symptoms and mortality are disproportionately more severe in people with obesity and obesity related comorbidities (2, 3). This is of concern for the United States, where ~42% have obesity and of these, 85% have type 2 diabetes."],"journal":"Obesity (Silver Spring)","authors":["Thomas, Diana M","Sturdivant, Rodney","Dhurandhar, Nikhil V","Debroy, Swati","Clark, Nicholas"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32386464","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/oby.22881","keywords":["covid-19","dynamic model","forecast","mathematical model","prediction","projection","statistical model"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1666340101968363520,"score":91.15545},{"pmid":32434708,"title":"SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.","text":["SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.","BACKGROUND: The novel coronavirus SARS-CoV-2 is associated with a severe respiratory manifestation, COVID-19, and presents a challenge for healthcare systems worldwide. Healthcare workers are a vulnerable cohort for SARS-CoV-2 infection due to frequent and close contact to patients with COVID-19. STUDY DESIGN: Serum samples from 316 healthcare workers of the University Hospital Essen, Germany were tested for SARS-CoV-2-IgG antibodies. A questionnaire was used to collect demographic and clinical data. Healthcare workers were grouped depending on the frequency of contact to COVID-19 patients in high-risk-group (n = 244) with daily contact to known or suspected SARS-CoV-2 positive patients, intermediated-risk-group (n = 37) with daily contact to patients without known or suspected SARS-CoV-2 infection at admission and low-risk-group (n = 35) without patient contact. RESULTS: In 5 of 316 (1.6 %) healthcare workers SARS-CoV-2-IgG antibodies could be detected. The seroprevalence was higher in the intermediate-risk-group vs. high-risk-group (2/37 (5.4 %) vs. 3/244 (1.2 %), p = 0.13). Four of the five subject were tested negative for SARS-CoV-2 via PCR. One (20 %) subject was not tested via PCR since he was asymptomatic. CONCLUSION: The overall seroprevalence of SARS-CoV-2 in healthcare workers of a tertiary hospital in Germany is low (1.6 %). The data indicate that the local hygiene standard might be effective.","J Clin Virol","Korth, Johannes","Wilde, Benjamin","Dolff, Sebastian","Anastasiou, Olympia E","Krawczyk, Adalbert","Jahn, Michael","Cordes, Sebastian","Ross, Birgit","Esser, Stefan","Lindemann, Monika","Kribben, Andreas","Dittmer, Ulf","Witzke, Oliver","Herrmann, Anke","32434708"],"abstract":["BACKGROUND: The novel coronavirus SARS-CoV-2 is associated with a severe respiratory manifestation, COVID-19, and presents a challenge for healthcare systems worldwide. Healthcare workers are a vulnerable cohort for SARS-CoV-2 infection due to frequent and close contact to patients with COVID-19. STUDY DESIGN: Serum samples from 316 healthcare workers of the University Hospital Essen, Germany were tested for SARS-CoV-2-IgG antibodies. A questionnaire was used to collect demographic and clinical data. Healthcare workers were grouped depending on the frequency of contact to COVID-19 patients in high-risk-group (n = 244) with daily contact to known or suspected SARS-CoV-2 positive patients, intermediated-risk-group (n = 37) with daily contact to patients without known or suspected SARS-CoV-2 infection at admission and low-risk-group (n = 35) without patient contact. RESULTS: In 5 of 316 (1.6 %) healthcare workers SARS-CoV-2-IgG antibodies could be detected. The seroprevalence was higher in the intermediate-risk-group vs. high-risk-group (2/37 (5.4 %) vs. 3/244 (1.2 %), p = 0.13). Four of the five subject were tested negative for SARS-CoV-2 via PCR. One (20 %) subject was not tested via PCR since he was asymptomatic. CONCLUSION: The overall seroprevalence of SARS-CoV-2 in healthcare workers of a tertiary hospital in Germany is low (1.6 %). The data indicate that the local hygiene standard might be effective."],"journal":"J Clin Virol","authors":["Korth, Johannes","Wilde, Benjamin","Dolff, Sebastian","Anastasiou, Olympia E","Krawczyk, Adalbert","Jahn, Michael","Cordes, Sebastian","Ross, Birgit","Esser, Stefan","Lindemann, Monika","Kribben, Andreas","Dittmer, Ulf","Witzke, Oliver","Herrmann, Anke"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434708","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jcv.2020.104437","keywords":["antibody detection","covid-19","healthcare workers","sars-cov-2","seroprevalence"],"locations":["Germany","Germany","Germany"],"countries":["Germany"],"countries_codes":["DEU|Germany"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393536794624,"score":85.629234},{"pmid":32397286,"title":"Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France.","text":["Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France.","The number of screening tests carried out in France and the methodology used to target the patients tested do not allow for a direct computation of the actual number of cases and the infection fatality ratio (IFR). The main objective of this work is to estimate the actual number of people infected with COVID-19 and to deduce the IFR during the observation window in France. We develop a `mechanistic-statistical' approach coupling a SIR epidemiological model describing the unobserved epidemiological dynamics, a probabilistic model describing the data acquisition process and a statistical inference method. The actual number of infected cases in France is probably higher than the observations: we find here a factor x8 (95%-CI: 5-12) which leads to an IFR in France of 0.5% (95%-CI: 0.3-0.8) based on hospital death counting data. Adjusting for the number of deaths in nursing homes, we obtain an IFR of 0.8% (95%-CI: 0.45-1.25). This IFR is consistent with previous findings in China (0.66%) and in the UK (0.9%) and lower than the value previously computed on the Diamond Princess cruse ship data (1.3%).","Biology (Basel)","Roques, Lionel","Klein, Etienne K","Papaix, Julien","Sar, Antoine","Soubeyrand, Samuel","32397286"],"abstract":["The number of screening tests carried out in France and the methodology used to target the patients tested do not allow for a direct computation of the actual number of cases and the infection fatality ratio (IFR). The main objective of this work is to estimate the actual number of people infected with COVID-19 and to deduce the IFR during the observation window in France. We develop a `mechanistic-statistical' approach coupling a SIR epidemiological model describing the unobserved epidemiological dynamics, a probabilistic model describing the data acquisition process and a statistical inference method. The actual number of infected cases in France is probably higher than the observations: we find here a factor x8 (95%-CI: 5-12) which leads to an IFR in France of 0.5% (95%-CI: 0.3-0.8) based on hospital death counting data. Adjusting for the number of deaths in nursing homes, we obtain an IFR of 0.8% (95%-CI: 0.45-1.25). This IFR is consistent with previous findings in China (0.66%) and in the UK (0.9%) and lower than the value previously computed on the Diamond Princess cruse ship data (1.3%)."],"journal":"Biology (Basel)","authors":["Roques, Lionel","Klein, Etienne K","Papaix, Julien","Sar, Antoine","Soubeyrand, Samuel"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397286","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/biology9050097","keywords":["bayesian inference","covid-19","sir model","case fatality rate","infection fatality ratio","mechanistic-statistical model"],"locations":["France","France","France","France","China","GBR","Diamond Princess","France"],"countries":["China","France","United Kingdom"],"countries_codes":["CHN|China","FRA|France","GBR|United Kingdom"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1666714494973247488,"score":82.78873}]}